Eligibility Question
To be answered at screening. If No, fill in the items of Inclusion and Exclusion criteria. Answer "no" corresponding to violations of any inclusion criteria, "yes" corresponding to violations of any Exclusion criteria. Do not enter the subject into the study if they failed any inclusion or exclusion criteria below.
text
Inclusion/Exclusion Criteria Check
Inclusion Criteria
A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to compromise subject safety or interfere with study integrity. Subjects with elevated prolactin values outside the normal range should always be excluded from enrollment.
boolean
Selected to encompass subjects without significant chance of brain function decline due to age.
boolean
Referral to dietician
boolean
a requirement to ensure consistency of fMRI signals from the brain
boolean
Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MIU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) will not be included in the study. Child-bearing potential and agrees to use one of the contraception methods listed for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 90 days after completion of the study. If female subjects are currently using oral or depot hormonal contraceptives, they may be enrolled but must also use one other form of contraception as listed. List of contraceptive methods with failure rate below 1 percent: * Abstinence: Sexual inactivity by abstinence must be consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Intrauterine device (IUD) or intrauterine system (IUS) that meets the under 1 percent failure rate as stated in the product label. * Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, “documented” refers to the outcome of the investigator's/designee’s medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records. * Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository).
boolean
This criterion must be followed from the time of the first dose of study medication until 90 days after completion of the study. List: * Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Double barrier method: condom plus spermicidal agent (foam/gel/film/cream/suppository).
boolean
BMI 27-40, comfortable body habitus
boolean
(Capable of) Written informed consent, Compliance with study requirements
boolean
QTcB or QTcF < 450 msec.
boolean
Beck Depression Inventory II < 13, Suicide question score = 0
boolean
Binge eating
boolean
TFEQ-R18 (Q3, Q6 and/or Q10 at least 3)
boolean
Exclusion Criteria
These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, psychiatric diseases or endocrine disease.
boolean
(with the exception of phase I hepatic impairment studies, oncology studies, hepatitis, hepatic fibrosis, or HIV studies).
text
closed angle glaucoma
boolean
prostatic hyperplasia
boolean
e.g. pacemaker, hearing aid, tattoos, metallic body piercing and/or other metal implants that cannot be removed.
boolean
Examples of such include, but are not limited to: schizophrenia or psychosis, major depressive disorder, anxiety disorders, stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson’s disease, vascular dementia, transient ischemic attack, rheumatoid arthritis and fibromyalgia syndrome.
boolean
Anorexia nervosa, Bulimia nervosa, Binge eating without obesity
boolean
Weight loss or gain > 5 percent in last 3 months
boolean
obesity surgery
boolean
Abuse of alcohol, defined for males, as an average weekly intake of greater than 21 units (or an average daily intake of greater than 3 units), or defined for females, as an average weekly intake of greater than 14 units (or an average daily intake of greater than 2 units). One unit is equivalent to a half-pint (220mL) of beer or 1 (25mL) measure of spirits or 1 glass (125mL) of wine.
boolean
Cotinine levels, History of smoking
boolean
Drug screen positive
boolean
Subjects above this limit may only be included if direct bilirubin is within normal limits, which would be consistent with Gilbert’s disease.
boolean
Lipid-lowering therapy
boolean
Diabetes mellitus Type 1/2, fasting plasma glucose, oral glycemic agent
boolean
Systolic or diastolic blood pressure above/below limits
boolean
Female subjects who are taking an oral contraceptive preparation at the time of screening may be eligible for enrolment in the study, however they must use additional forms of contraception.
boolean
current or planned pregnancy, hCG test
boolean
Lactating
boolean
* use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication with the exception of occasional non-daily use of acetaminophen, or non-steroidal anti-inflammatory agents. * Use of weight loss drugs within three months of the first dose of the marketed drug. * Use of any oral anti-diabetic medication (including metformin, sulphonylureas, thiazolidinedione, GLP-1 agonist, DDP-IV inhibitors). * Use of antidepressants or anxiolytics (selective serotonin re-uptake inhibitor (SSRI), tricyclic, buprion, sedatives, hypnotics) on any basis other than occasional within 6 months of screening. * Use of antipsychotics (i.e. D2 antagonists) or any dopamine agonists (i.e. bromocriptine, pergolide) or Parkinson’s disease medications (L-DOPA) ever * Use of diuretics, systemic corticosteroids (inhaled and intranasal corticosteroids are permitted), or any other medication within 3 weeks prior to any scheduled dose of study medication that may result in electrolyte depletion. * Use of macrolide antibiotics during the interventional part of the study. Medications not allowed: At least 6 months prior to the Baseline Visit: All antidepressants, Lithium At least 2 weeks prior to Baseline visit (or 5 half-lives whichever is longer): Psychoactive herbal or nutritional treatment (e.g., St. John's Wort, SAM-e), Opiates, hypnotics, anxiolytics, and all other sedatives (including as needed benzodiazepines as sleep aids), Systemic corticosteroids (NOTE: Topical hydrocortisone, inhaled and nasal corticosteroids are allowed). Concomitant medications that are known potent or moderate inducers or inhibitors of CYP3A4/5 for 14 days prior to administration randomization through 14 days after the last dose of investigational product: CYP3A4/5 Inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil (Intermittent use of topical/vaginal antifungal medications are permitted), CYP3A4/5 Inducers: carbamazepine, phenobarbitol, phenytoin, rifabutin, rifampicin, St John’s Wort. Please note that this is not an exhaustive list.
boolean
Investigational drug or device in last 12 months
boolean
Sensitivity to study medication, other (drug) allergy
boolean
Study participation resulting in Blood donation
boolean
Red wine, seville oranges, grapefruit (juice)
boolean
Serum Prolactin
boolean
DSM-IV Axis I or II
boolean
QTc prolonged, arrhythmia, sudden unexplained death/syncope in first degree relative
boolean
Protocol compliance unwilling/unable
boolean
Healthy food preference
boolean